Healthy Volunteer
Conditions
Brief summary
This is a phase 1b, open-label, single dose study in healthy male subjects. Approximately 12 healthy male subjects will receive a subcutaneous injection of denosumab on Day 1. Subjects will be followed by a 105 day treatment-free follow-up period.
Interventions
BIOLOGICALDenosumab
60 mg
Sponsors
Amgen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Subject has provided informed consent; Healthy male between ≥40 to ≤ 65 years of age (inclusive) at the time of enrollment; Subject must be willing and able to produce a semen sample on seven separate study visits; Subject must be willing to refrain from ejaculation for a 48 hour period prior to each sample collection;
Exclusion criteria
Any condition or drug therapy that might interfere with the subjects ability to ejaculate and produce a semen sample; Clinically significant abnormality during the screening physical examination, ECG, or laboratory evaluation; Known history of blood in urine or semen; Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease; Recent tooth extraction (within 6 months of screening visit); Evidence of hypocalcemia at screening; Known vitamin D deficiency; Malignancy (except non-melanoma skin cancers) within the last 5 years; Positive for human immunodeficiency virus (HIV) at screening or known diagnosis of AIDS; Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B) or detectable Hepatitis C virus Ribonucleic acid (RNA) by Polymerase Chain Reaction (PCR) at screening (indicative of active Hepatitis C - screening is generally done by Hepatitis C Antibody (HepCAb), followed by Hepatitis C virus RNA by PCR if HepCAb is positive); History of hypersensitivity or allergic reaction to mammalian cell derived drug products or sensitivity to any of the products or components to be administered during dosing; Known intolerance to calcium or vitamin D supplements; Subject previously has entered this study or has been previously exposed to denosumab in the past 12 months; Has donated or lost ≥ 400 mL of blood or plasma within 8 weeks prior to screening; Positive urine screen for alcohol and/or potential drugs of abuse at screening unless medication is prescribed by a physician and approved by the Investigator and Amgen; Known alcohol abuse or use of illicit drugs within 12 months of enrollment; Subject is unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to screening and administration of investigational product. Alcohol is limited to no more than 2 drinks per day for the duration of the study; where a standard drink is equivalent to 12 ounces of regular beer, 8-9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits; Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded; Use of any non-Amgen approved over-the-counter or prescription medications, within the 14 days or 5 half-lives (whichever is longer), prior to receiving the dose of denosumab. Acetaminophen (up to 2 g per day) for analgesia and hormone replacement therapy (eg, androgen, thyroid) will be allowed. Other medications may be approved following review by the Principal Investigator and the Amgen Medical Monitor. Written documentation of this review and Amgen acknowledgement is required for subject participation; Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge; Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures; History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid | Days 1, 10, 22, 36, 50, 78 and 106 | — |
| Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid | Days 1, 10, 22, 36, 50, 78 and 106 | — |
| Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid | Days 1, 10, 22, 36, 50, 78 and 106 | The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio) | Days 1, 10, 22, 36, 50, 78 and 106 | The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio) |
| Maximum Observed Concentration (Cmax) of Denosumab in Serum | Days 1, 10, 22, 36, 50, 78 and 106 | — |
| Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106). | Day 106 | — |
| Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period | Days 1, 10, 22, 36, 50, 78 and 106 | The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period. |
| Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum | Days 1, 10, 22, 36, 50, 78 and 106 | — |
| Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum | Days 1, 10, 22, 36, 50, 78 and 106 | The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method. |
Countries
United States
Participant flow
Recruitment details
First patient enrolled 17 June 2013; last patient enrolled 17 June 2013.
Participants by arm
| Arm | Count |
|---|---|
| Denosumab Participants received a single subcutaneous injection of 60 mg denosumab on Day 1. | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | Denosumab |
|---|---|
| Age, Continuous | 56.6 years STANDARD_DEVIATION 7 |
| Body Mass Index (BMI) | 27.73 kg/m^2 STANDARD_DEVIATION 4.21 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 participants |
| Race/Ethnicity, Customized Asian | 0 participants |
| Race/Ethnicity, Customized Black (or African American) | 0 participants |
| Race/Ethnicity, Customized Mixed race | 0 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 participants |
| Race/Ethnicity, Customized Othe | 1 participants |
| Race/Ethnicity, Customized White | 11 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 5 / 12 |
| serious Total, serious adverse events | 1 / 12 |
Outcome results
Primary
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid
The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid | 5220 days*ng/mL | Standard Deviation 4880 |
Primary
Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid | 100 ng/mL | Standard Deviation 81.9 |
Primary
Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population with available data
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Denosumab | Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid | 21 days | Full Range 81.9 |
Secondary
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum
The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum | 333000 days*ng/mL | Standard Deviation 122000 |
Secondary
Maximum Observed Concentration (Cmax) of Denosumab in Serum
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Maximum Observed Concentration (Cmax) of Denosumab in Serum | 6170 ng/mL | Standard Deviation 2070 |
Secondary
Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).
Time frame: Day 106
Population: Pharmacokinetic population with available data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106). | 0.0197 ratio | Standard Deviation 0.0318 |
Secondary
Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)
The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population with available data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio) | 0.0217 ratio | Standard Deviation 0.0154 |
Secondary
Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period
The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Denosumab | Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period | 0.0170 ratio | Standard Deviation 0.0148 |
Secondary
Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Population: Pharmacokinetic population
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Denosumab | Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum | 8.0 days | Full Range 81.9 |